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Abstract 
As well-established for patients with chronic pain, patients suffering from chronic itch also exhibit 
signs of peripheral and central sensitization. This has been linked to parallel neuroplastic 
sensitization processes. However, for chronic itch, sensitization has not yet been systematically 
assessed, studied, and hence validated. This review (Prospero CRD42016043002) summarizes and 
meta-analytically evaluates whether sensory aberrations including sensitization for itch occur in 
chronic itch.  
Databases PubMed, Embase, and Cochrane Library were searched for studies investigating 
somatosensory sensitivity assessment by quantitative sensory testing stimuli, including 
experimental cutaneous chemical pruritic provocations, in patients with chronic itch from skin-
/neurological conditions and compared with healthy controls. Outcomes were extracted for lesional 
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and non-lesional skin and risk of biases were assessed. Meta-analyses were performed when 
sufficient quantitative data were available.  
Of 4,667 identified papers, 46 were included and 25 were eligible for meta-analyses. Patients (66% 
atopic dermatitis) were found more sensitive than the controls to histamine-evoked itch in lesional 
skin (SMD: 0.66 [CI: 0.16,1.15]), but not non-lesionally (SMD: -0.26 [CI: -0.58;0.06]). Cowhage 
did not evoke more itch in non-lesional skin of patients as compared to the controls (SMD: 0.38 
[CI: -0.04,0.81]). For numerous other chemical provocations as well as for mechanical, thermal, and 
electrical stimulation paradigms, results were ambiguous or based on few studies.  
Patients with chronic itch are only robustly sensitized to various chemical pruritic stimuli when 
applied lesionally. More studies on somatosensory aberrations in chronic itch conditions other than 
atopic dermatitis are needed to establish whether sensitization is robustly present across chronic itch 
conditions. 
Key words: Pruritus; hyperknesis; alloknesis; pain; central sensitization; peripheral sensitization; 
neuroplasticity; quantitative sensory testing 
 
1. Introduction  
Itch is an unpleasant sensation, distinct from pain, characterized by evoking a desire to scratch the 
affected area. Most individuals experience occasional acute episodic itch, which usually resolves 
spontaneously within hours or days.27,82,105 However, chronic itch (defined as lasting more than 6 
weeks108) is also associated with cutaneous pain and dysesthesias, and profoundly impacts quality 
of life e.g., by interfering with sleep, attention, and affective functions.51,82 Chronic itch is the 
primary sensory symptom in a wide range of skin, neuropathic , systemic  and drug-induced 
conditions.108,125 With a point prevalence of chronic itch estimated between ≈5-15%, and largely 
suboptimal treatment options, chronic itch represents a significant socioeconomic burden.82  
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Notably, the pathomechanisms driving chronic itch in prevalent skin conditions, such as atopic 
dermatitis, and itch of neurological origin, remain largely unknown. Neuronal sensitization 
occurring both in the periphery and in the central nervous system has been suggested to play a 
role as has been established for pain.14,15,26,67,114 
 
While pain sensitization has been extensively studied in animals, human surrogate models and 
patients,4,99 sensitization for itch has only been sparsely investigated. This is somewhat 
surprising given that the first attempts to study histamine skin responses were early in the 20th
century and, while signs of itch sensitization in patients were studied for the first time some 
decennia thereafter.21,22,30 Cormia et al. (1952 and 1953) meticulously investigated differences in 
“itch threshold” by serial diluted intradermal histamine injections in patients with chronic itch of 
various origins versus healthy controls.21,22 Additionally, Shelley and Arthur (1955) used various 
modalities, including mucunain from cowhage spicules and trypsin, to probe itch sensitivity in 
various pruritic conditions and as well as during extensive array of experimental 
manipulations.104 The recent discovery of: parallel afferent itch pathways50,74 (the neuronal 
encoding remains enigmatic52,63), endogenous receptors of mucunain-induced itch,87,88 spinal 
circuitry involved in itch transmission/modulation2,16,90,110 as well as several novel molecular 
substrates involved in pruritic signaling42,73,87,127 has spawned renewed interest in studying 
whether patients suffering from chronic itch become sensitized akin to what has been shown in 
chronic pain patients.5,8,99,128 
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1.1. Defining sensitization 
Sensitization in the context of pain as well as itch refers to a state of increased responsiveness of 
nociceptive and pruriceptive neurons, respectively, to their normal or subthreshold afferent 
input.34,98,112 In the field of pain research, the molecular mechanisms and behavioral as well as 
psychophysical manifestations of sensitization have be n intensively studied.64,98,128 Sensitization 
is usually classified as being either peripheral (affecting primary afferent nociceptors) or central 
(affecting nociceptors in the central nervous system), and often both may play a role in chronic 
itch and pain conditions. Particularly the denotatin of central sensitization is associated with 
ongoing definitional contention,20,55,98 in part because the underlying pathophysiology is 
currently not fully understood.128 Central sensitization may also be aggravated by 
biopsychosocial factors, such as anxiety, increased attention, and negative expectations.1,97,117 
For the present paper, the term sensitization is used in the broadest sense. As a proxy of 
sensitization, an increased psychophysical sensitivity in patients compared to that of healthy 
controls in response to a controlled somatosensory timulus (often designed to evoke itch) has 
often been studied. While an increased psychophysical ensitivity is plausibly a reflection of 
increased responsiveness of peripheral and/or central pruriceptive nociceptors, direct evidence 
hereof is seldomly present in human studies.34,98 Nevertheless, it can often be inferred whether 
underlying processes are likely to be manifesting at a peripheral or central level (e.g. when 
stimulating on lesional or non-lesional skin, respectiv ly). While much is known about 
mechanisms of pain sensitization, relatively little is known about the mechanisms causing 
sensitization specifically for itch. They appear to largely, if not entirely, overlap with the 
processes leading to sensitization for pain.46,95 A thorough recapitulation of the mechanisms 
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behind neuronal sensitization is beyond the scope of the present study and we instead refer to 
previous excellent reviews.8,98,102,128  
 
1.2. Probing sensitization for itch and pain  
Not only are the underlying mechanisms of sensitizat on for itch and pain thought to be largely 
shared, but painful and pruritic stimuli also induce strikingly similar dysesthesic 
manifestations.5,99,107 Within and immediately surrounding the area of painful stimuli, allodynia 
and hyperalgesia may develop.69,98 Completely analogue hereto but occurring in the context of 
itch, are alloknesis, describing the state in which an otherwise non-pruritic stimulus, such as light 
tactile stimuli, provoke a sensation of itch (similar to allodynia),12,106 and hyperknesis, describing 
an increased itch response elicited upon a normally pruritic stimulus, e.g. by means of 
mechanical probing or a chemical itch provocation (similar to hyperalgesia).10,17,44 These 
dysesthesias, suggested constitute signs of sensitization, are not only experimental phenomena – 
they also occur in (and can be highly bothersome for) patients with acute and chronic itch or 
pain.7,44,120 Quantitative sensory testing (QST) for experimental i ch and pain sensitivity 
assessment is multimodal, i.e. include thermal, mechani al, electrical, and chemical stimuli. 
These can be applied to various tissues including muscles, viscera, and skin, with the latter 
naturally being the most commonly used substrate for QST in chronic itch patients given that 
itch exclusively arises from the skin and certain mucosal tissues.9,108,116 Standardized stimuli can 
be delivered to assess detection thresholds, itch/pain thresholds and supra-threshold reactivity 
corresponding to different transduction receptors, primary afferent populations and CNS 
pathways.29,31 With this approach, specific localized or systemic sensory aberrations (e.g., 
reduced thermal detection thresholds in small fiber n uropathy or increased itch responses to 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
   4 / 29
mechanical stimuli), can be identified, linked to, and act as proxy measures of an ongoing 
pathophysiological process.43,44,66  
 
While there is a substantial volume of literature on the study of QST methodology and sensory 
aberrations occurring in pain patients,8,9,18,66 QST studies in the field of itch research are rather 
scarce and often more methodologically heterogeneous. Numerous recent studies have 
investigated somatosensory sensitivity in patients wi h chronic itch versus healthy controls. This 
first systematic review in the field comprehensively summarizes and meta-analytically evaluates 
if, and the degree to which, aberrations including sensitization for itch occur in response to 
somatosensory stimuli in conditions characterized by chronic itch resulting from skin or 
neurological conditions as opposed to healthy controls. 
 
2. Methods  
2.1. Protocol and registration 
This review was performed in accordance with the PRISMA Statement (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses; see Suppl. Table 1 for the PRISMA 
Checklist, available at http://links.lww.com/PAIN/A858) and the recommendations of the 
Cochrane Collaboration (www.cochrane-handbook.org) where applicable.40,65 The study protocol 
was prospectively published in the Prospero registry under the no.: CRD42016043002. 
 
2.2. Information sources and searches 
The electronic databases PubMed, Embase, and the Cochrane Library were searched from 
inception until 7 March 2018 by one reviewer using terms related to itch conditions (e.g., chronic 
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prurit*) and quantitative sensory testing (QST) stimuli (e.g., QST and mechanic*). It was chosen 
to explicitly search for all kinds of somatosensory stimuli, because most of the studies do not 
explicitly use the term “quantitative sensory testing” or a comparable term covering the field. No 
limits to the search terms were applied with regard to publication date, language, or article type. 
Within the search, all papers that were classified as animal studies without the classification of 
“human study” were excluded. The PubMed search strategy has been added as Suppl. Table 2 
(available at http://links.lww.com/PAIN/A858). For the other databases, comparable terms, e.g., 
MeSH and EMTREE, were used. 
 
2.3. Eligibility criteria  
Studies were included when fulfilling the following criteria: experimental/observational study in 
which somatosensory sensitivity was quantified by means of QST in patients with a 
dermatological or neurological condition (classified in accordance with the International Forum 
for the Study on itch (IFSI) etiological subgrouping of chronic pruritus, category I and III108) and 
healthy controls (the inclusion of healthy controls is essential because cutaneous and sensory 
changes may occur in patients even in non-lesional skin). Studies were excluded when the 
majority of the patients had another primary condition than outlined above, such as pruritus 
associated with a systemic disorder, when lacking a control group, and when itch was not induced 
by somatosensory stimuli (e.g., by use of visual or auditory stimuli) or not quantified by common 
psychophysical techniques, such as thresholds or numerical ratings for itch.103 Only full-text 
studies displaying previously unpublished data in English peer-reviewed journals, published after 
1980 were included.  
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2.4. Study selection 
The titles and abstracts obtained in the searches were screened by one reviewer according to the 
eligibility criteria. Of potentially eligible studies, including those for which there was any doubt 
about their eligibility based on the abstract, the full text articles were retrieved via university 
libraries (Aalborg and Leiden University) or by requesting the article from the study authors. The 
eligibility of all full-text articles was evaluated using a pre-piloted standardized sheet by two 
reviewers. A third reviewer was involved if there was doubt or disagreement about article 
eligibility. Studies that fulfilled the criteria for inclusion were included in the systematic review.  
 
2.5. Data collection and extraction 
Using pre-piloted forms, the following data were extracted from the included studies by one 
reviewer and checked by a second reviewer: population characteristics (e.g., diagnosis, sample 
sizes, demographics), details on the QST stimuli and their application sites (including application 
on lesional or non-lesional skin), and relevant data on the somatosensory outcome measures. For 
the latter, the direction of a potential difference along with the significance levels when 
comparing the patient and control group were collected. The following was considered: 1) for 
similar provocations, different modes of application, concentrations, or current intensities were 
pooled across studies; 2) if a study used multiple measurement sites, the results from the most 
commonly used location was taken (e.g., the forearm) 3) data obtained from lesional or non-
lesional skin of patients with itch were preferably compared to those of corresponding areas in 
the healthy controls (data from lesional and non-lesional skin were never pooled); 4) if a study 
used multiple concentrations of a compound or multiple stimulus intensities (e.g., electrical 
current), the highest concentration/intensity of the stimulation was included; 5) if different 
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subgroups of patients were included (e.g. acutely exac rbated vs. latent AD) and the study 
authors made separate statistical comparisons, the comparison between healthy controls and the 
most severely affected subgroup was extracted; 6) outcomes related to the duration of the itch 
sensation were not included as barely any study record d the time point of complete abolishment 
of the itch sensation; 7) data on wheal size were not included since wheal is an entirely non-
neuronal response13; 8) for patients with sensitive skin symptomatic versus asymptomatic skin 
areas were referred to as lesional versus non-lesional, respectively. When data of one 
somatosensory outcome were available from at least five studies, mean and standard deviation 
(SD)/standard error of the mean (SEM) of the somatosensory outcome measures were extracted 
for the quantitative meta-analysis from text, tables, figures, or by contacting the study authors. 
Consensus about ambiguities between the first and second reviewer in relation to any variable 
within the forms was reached by discussion and potential involvement of a third reviewer. In the 
case data of one or more studies were missing (and coul  not be retrieved via contact with the 
study authors) while there were in total sufficient studies to perform a meta-analysis on the 
respective outcome, these studies were neither included in the meta-analysis nor in the semi-
quantitative overview to avoid presenting the same outcome twice.  
 
2.6. Risk of bias assessments 
The risk of bias (RoB) assessment tool developed by Marcuzzi and colleagues68 specifically for 
assessment of RoB in QST studies was adjusted. In the original tool, the word “pain” was 
substituted for “itch” and the criterion of ‘blinding of assessments’ was omitted as blinding with 
respect to skin conditions is unfeasible, particularly when testing on lesional skin. The adjusted 
tool took the following criteria into account: 1) clarity of sample description with regard to 1a) 
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addressing inclusion and exclusion criteria (e.g., cutoffs for participants’ age, description of the 
diagnostic criteria), 1b) demographic characteristics (e.g., sample size, gender percentages, mean 
clinical itch duration and intensity), 1c) the recruitment procedure (e.g., how participants were 
recruited); 2) quality of somatosensory assessments with regard to 2a) whether somatosensory 
assessments were following a standardized or validated procedure, 2b) the comprehensiveness of 
somatosensory assessment description (e.g., whether the quipment, the number of assessments 
and the measurement sites had been described as well as reporting on whether stimuli were 
applied at lesional or non-lesional skin); 3) whether factors known to influence itch perception 
and assessment of neurogenic inflammation were evaluated and controlled for (e.g., medication 
intake, age, gender, room temperature, and humidity). Using this adjusted tool, the RoB for all 
included studies was scored independently by two reviewers. Discrepancies in scoring were 
identified and resolved through discussion, with potential involvement of a third reviewer. Each 
criterion was scored as satisfied (’low RoB’) when the majority of the items within that criterion 
were fulfilled, not satisfied when the majority of the items within the criterion was not fulfilled 
(’high RoB’) or partially satisfied when aforementioned information was unclearly presented 
(‘unclear RoB’). Individual studies were given an overall score for RoB by summing the scores 
for the seven criteria. A score of 1, 0.5, and 0 was given for high, moderate (‘unclear’), and low 
RoB, respectively. Studies with an overall score >3 were judged as high, between 2 and 3 as 
moderate, and <2 as low RoB. In order to assess the RoB across studies included in the 
quantitative meta-analyses, funnel plots were created.  
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2.7. Data synthesis and analyses 
For outcomes described in at least five included studies with similar provocations, the 
standardized mean differences (SMDs) were calculated based on available means and SDs (with 
SEMs being transformed to SDs) of the patient and control condition for the quantitative meta-
analysis. Sufficient data were available for the following stimulus modalities: 1) histamine-
induced itch (pooled AUC/mean and peak; applied at non-lesional and lesional skin of patients in 
comparison to healthy controls), 2) non-histaminergic induced itch (pooled AUC/mean; on non-
lesional skin in comparison to healthy controls), and 3) histamine-induced neurogenic flare 
reactions on non-lesional skin in comparison to healt y controls. For each meta-analysis, a study 
was only included once (see considerations in paragr ph 2.5), except for when results were 
presented per patient group, in which case the datafor each patient group were taken into 
account. Random effects models were used to statically pool the data and Forest plots were 
made. A priori planned secondary subset analyses for the different itch conditions were not 
feasible since the vast majority of studies involved patients with AD. For the meta-analytic 
outcomes an overall effect size was calculated across all included conditions. However, due to 
the distinct pathoetiologies involved in different chronic itch conditions such estimates should be 
interpreted with caution. Sensitivity analyses were planned by performing the same random-
effects meta-analysis after excluding studies with an overall high RoB score. Heterogeneity of 
effects was assessed by I2 statistics, with 25%, 50% and 75% indicating low, moderate, and high 
degrees of heterogeneity, respectively.19 Visually, heterogeneity (e.g., due to reporting bias) was 
inspected using funnel plots when at least 10 studies were included for the respective quantitative 
outcome. For somatosensory outcomes described in less than five studies, data were aggregated 
to display whether the patients showed a significant (p < 0.05) increase, decrease, or was not 
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significantly different (p > 0.05) from the healthy control group for semi-quantitative analyses. 
Review Manager Version 5.3 (RevMan; Copenhagen: TheNordic Cochrane Centre, the 
Cochrane Collaboration, 2014) was used to conduct the s atistical analyses and display the RoB 
assessments. 
 
3. Results 
3.1. Study characteristics 
3.1.1. Study selection 
From the search strategy, 4,667 articles were retrieved. After screening the titles and abstracts of 
3,769 articles, 66 full text articles were screened, of which 20 were excluded (see flow diagram 
in Figure 1). The reasons for exclusion were that te study did not include either patients (n=6) 
or healthy controls (n=3), that there was no direct comparison between the patients and control 
(n=2), that there was no somatosensory provocation (n=3), that stimulation methodology differed 
across both groups (n=1), that itch was modulated, but a baseline rating was missing (n=1), or 
that itch was not assessed or not in a standard manner ( =4). Of the remaining 46 studies that 
were included in the review based on the inclusion criteria, 25 could be included in the 
quantitative meta-analysis. 
 
3.1.2. Study characteristics 
Of the included studies (see Table 1 for the study characteristics), the majority studied patients 
with AD (n=32), followed by ‘mixed’ patient populations with chronic itch due to skin 
conditions (n= 6), psoriasis (n= 2), prurigo nodularis (n=2), chronic post-burn itch, sensitive 
skin, primary localized cutaneous amyloidosis, and central centrifugal cicatricial alopecia (all 
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n=1). In total, 932 patients (n= 612 patients with AD) and 822 healthy controls had been 
included. Note that due to the overrepresentation of i cluded studies conducted in patients with 
AD, it is important to keep in mind that many of deriv d results may predominantly apply to this 
specific chronic itch condition. Chemical stimuli had been applied in 38 studies, mechanical 
stimuli in 15 studies, thermal stimuli in 12 studies, and electrical stimuli in 11 studies (Table 1). 
Whereas in most studies patients were tested only on non-lesional skin (n=23), 9 studies tested 
patients on both lesional and non-lesional skin, 5 studies tested only on lesional skin, and for 4 
studies this is unknown. Neurogenic inflammatory responses appear to have been systematically 
characterized across multiple studies in response to chemical provocations only.  
 
3.1.3. Risk of bias assessment 
Of the 46 included studies, 14 were judged as having overall low RoB (i.e. RoB score <2), 32 
studies were judged as having overall moderate RoB (i.e. RoB score 2-3), and no studies were 
considered as having overall high RoB (i.e. RoB score >3). For this reason, sensitivity analyses 
were not conducted for the quantitative analyses. 
 
Per criterion (see Figure 2 for an overview; and Suppl. Fig. 1 for the RoB scores per study, 
available at http://links.lww.com/PAIN/A858), particularly the recruitment procedure (criterion 
1c) was not (n= 38 high RoB), or inadequately described (n=1 moderate RoB). Also, the in- and 
exclusion criteria (criterion 1a) were often not reported (n=17 high RoB) or poorly described 
(n=6 moderate RoB). The demographics and sample chara teristics (criterion 1b) were generally 
well described (n=20 low RoB, n=3 moderate RoB), and were characterized as high RoB in three 
studies, for instance when both the gender distribution and the intensity and duration of patients’ 
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clinical itch were not reported. All studies described the somatosensory assessment methodology 
(criterion 2b) adequately (n=44 low RoB and n=2 moderate RoB). Somatosensory assessments 
rarely followed a standardized or validated procedur  (criterion 2a) for itch provocations and 
QST stimuli were rarely designed specifically to probe the pruriceptive system, because of the 
novelty of the field and the lack of a “gold standard” to probe itch sensitization. Therefore, this 
criterion was evaluated as ‘low’ RoB in only 3 studies and ‘moderate’ RoB for the remaining 43 
studies. Half of the studies described and controlled for factors that may influence the 
somatosensory assessment/outcomes (criterion 3) and were judged ‘low’ RoB (n=23), whereas 
the other half was judged ‘moderate’ RoB.  
 
Across the studies included in the quantitative meta-analyses, statistical heterogeneity was 
moderate for two outcomes (i.e. an I2 statistic of 50% for non-histaminergic evoked mean itch on 
non-lesional skin and 66% for histamine evoked mean itch on lesional skin) and high for the 
other 4 outcomes (76% for histamine-evoked mean itch on non-lesional skin, 77% and 75% for 
histamine evoked peak itch on lesional and non lesional skin respectively, and 89% for histamine 
flare reactions on non-lesional skin). Inspection of the funnel plots that included at least 10 
studies mainly indicates heterogeneity for the outcmes of histamine-evoked peak itch and 
histamine-induced flare both when comparing the non-lesional skin of patients with the controls. 
This is mainly due to two studies, which deviate from the symmetry in the direction of less 
sensitivity of the patients compared to the controls.37,94 In relation to the overall publication 
diversity, a few research groups have published more than two papers eligible for inclusion in the 
quantitative analyses.  
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3.2 Chemical stimuli 
The majority of the included studies applied chemical provocation to elicit both sensory 
responses, i.e. itch and/or pain, as well as neurognic inflammatory responses. Most studies used 
well-known pruritogens or algogens applied either by intradermal injection, iontophoresis or skin 
prick/puncture. The most frequently studied substance is by far histamine followed by agonists 
of the PAR2/4 and/or the MRGPRX1/286,89 (i.e. cowhage and SLIKGV). No other chemical 
provocations have been performed in at least 5 studies on patient populations with chronic itch. 
Cutaneous chemical provocations using 14 distinct chemicals were identified in the literature.  
 
3.2.1. Histamine-induced itch 
Results from chronic itch patients suggest that histamine provocations do not evoke increased 
itch responses (AUC/mean) in non-lesional skin (Fig. 3) but rather a trend towards decreased itch 
sensitivity is evident (k = 20, SMD: -0.26 [CI: -0.58;0.06]). The outcome is characterized by 
substantial heterogeneity including a single outlying study in the AD subgroup.37 For the 
outcome of peak itch intensity similar results were observed (k = 11, SMD: -0.29 [CI: -
0.72;0.14]) substantiating the lack of robust sensitivity alterations for histamine in non-lesional 
skin (Suppl. Fig. 2, available at http://links.lww.com/PAIN/A858). Oppositely, histamine evokes 
significantly more itch in lesional skin of chronic it h patients compared to healthy controls (Fig. 
4), indicating intra-lesional sensitization to histamine. This effect is driven solely by studies on 
AD (k = 5, SMD: 0.92 [CI: 0.32;1.53]) and no increas d sensitivity is apparent for PSO or 
CCCA. This observation is also consistent with data extracted for the outcome peak itch where 
increased responses to histamine were observed in lesional skin only in the AD patients (k = 3, 
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SMD: 1.07 [CI: 0.56;1.57]), and not overall (k = 5, SMD: 0.58 [CI: -0.10;1.25]), see Suppl. Fig. 
3 (available at http://links.lww.com/PAIN/A858).  
 
3.2.2. Non-histaminergic itch 
For non-histaminergic itch stimuli, induced by cowhage and SLIGKV, only the mean itch 
outcome was available in the minimally required 5 studies and only for non-lesional skin. Only a 
single study performed intra-lesional cowhage provocati ns in AD,6 and one other study injected 
SLIGKV; both in AD.109 Both studies documented significantly increased itch responses in the 
AD patients. Administration of cowhage in non-lesional skin of chronic itch patients did not 
evoke significantly more itch than in healthy contrls (Fig. 5), although a trend towards 
increased itch in patients was evident (k = 6, SMD: 0.38 [CI: -0.04, 0.81]). These results were 
obtained across several different chronic itch conditions. Notably, results of 5 out of 6 studies 
were well-aligned, showing trending or significant i creases in cowhage-induced itch sensitivity 
in patients, while only Nattkemper et al. (2015) found insignificantly reduced responses to 
cowhage.75  
 
3.2.3. Miscellaneous chemical provocations 
In the 38 out of 46 studies with chemical provocations, 14 different algogens and pruritogens 
have been tested in chronic itch patients versus matched healthy controls (Table 1 and 2). Highly 
varied responses were observed across studies. Several of the chemical provocations were found 
to induce significantly more itch in patients in single studies and delivered opposite results in 
others. Many of the applied provocations, which are consistently found to induce similar itch 
intensities, particularly in non-lesional skin of chronic itch patients versus healthy controls, are 
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partially or completely histamine-dependent, e.g. compound 44/80 or codeine. Consequently, no 
sensory sensitization to a particular chemical provocation, aside from histamine, is evident in 
patients suffering from chronic itch. However, these findings remain to be reproduced. In three 
studies, a remarkable shift in perception of the sensation quality towards stronger itch and less 
pain was observed in chronic itch patients when subjected to an intra-lesional cutaneous 
provocation with an algogen. This phenomenon, tentaively termed ‘algoknesis’ (i.e. itch in 
response to a stimulus which is normally perceived as painful), has been observed in patients 
with AD, e.g. in response to an acidic provocation,44 mustard oil,35 and bradykinin,43 all of which 
are normally considered prototypical algogens, which predominantly or exclusively evoke pain 
in healthy skin. 
3.2.4 Neurogenic inflammatory responses  
In the present review, only the neurogenic inflammatory responses to histamine were eligible for 
meta-analysis (Fig. 6). However, numerous chemical provocations capable of evoking 
neurogenic inflammation have been tested in chronic itch patients (see Table 2). For neurogenic 
inflammatory responses to histamine, very consistent results are evident. In 11 out of 12 studies 
in non-lesional skin of AD patients, histamine induced significantly smaller neurogenic flare 
reactions than in the healthy controls (k = 12, SMD: -1.42 [CI: -1.99, -0.84]). A similarly 
reduced neurovascular reactivity has been observed in urticaria in a single study,37 but not in 
PSO (two studies3,37) nor in in patients with sensitive skin (one study24). Reduced neurovascular 
reactivity to chemical provocations in AD is not only observed in response to histamine but has 
also been reported in response to acetylcholine91, the mast-cell degranulator compound 
48/80,94,120 IL-2,122 substance P,35 and VIP91 (Table 2). Despite the numerous studies on 
chemically evoked neurogenic inflammation in patients with chronic itch, increased responses 
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are never observed irrespective of the applied chemical. Only a few studies have attempted to 
address alterations in neurogenic inflammatory reactivity intra-lesionally.6,43 Reliable 
measurements of neurogenic inflammatory responses in les onal skin is usually unfeasible as 
most of the studied chronic itch conditions are associated with substantial erythema prior to any 
chemical provocations.6 Modern microvascular blood flow imaging techniques nables the 
assessment of neurogenic flare intensity as opposed to simply the size of the reaction. Such 
assessments have been performed in a handful of studie  with results generally showing no 
differences or a reduced reaction intensity not only to histamine6 but also to, e.g. cowhage32, IL-
3133, mustard oil,35 substance P,35 and prostaglandin E2.76 
 
3.3. Mechanical stimuli  
A diverse range of mechanical probing techniques have been used in patients with chronic itch 
conditions (Table 3). Most tools, e.g. von Frey or pin prick stimulators, specifically test the 
sensitivity of the superficial skin fibers, while a more recent study included assessment of the 
pain sensitivity of deeper tissues. The diversity of assessment approaches is paralleled by diverse 
results. As for other outcomes the majority of studies are conducted in patients with AD. A 
couple of notable findings for lesional and non-lesional skin are reproduced in multiple studies; 
1) mechanical detection thresholds are increased,6,101 2) alloknesis to brush strokes or wool fibers 
is present43,120 and 3) hyperknesis to punctate stimuli, e.g., von Frey filaments and pin pricks, is 
evident.6,44,60,101 Mechanical and pressure pain thresholds in lesional a d non-lesional skin of 
patients do generally not differ from the healthy controls. Some studies report pinprick 
hyperalgesia in lesional and non-lesional skin of patients with chronic itch,6,101 but others found 
no difference between patients and healthy controls.44,84   
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As opposed to the in situ assessment of mechanical sensory sensitivity describ d above, 
numerous studies have assessed mechanically evoked itch sensitivity following various types of 
precipitating itch stimulations. The two techniques commonly used for quantifying the increases 
in mechanical itch sensitivity perifocally associated with itch provocations involve either 
quantifying the total extent of the area (e.g. of alloknesis or hyperknesis) or the intensity of these 
itch dysesthesias.4 Both techniques have almost exclusively been performed in non-lesional 
areas, although a few exceptions exist.6,44 Generally, studies quantifying the extent of the 
dysesthesic areas do not find significant differences between healthy controls and chronic itch 
patients45,124 (two studies even found reduced mechanical itch dysesthesias in patients following 
a histamine provocation38,126). Oppositely, when quantifying the intensity of the chemically 
induced itch dysesthesias, more severe dysesthesias appear to develop in chronic itch patients as 
compared to healthy controls.6 The literature on occurrence and mechanisms of mechani al itch 
dysesthesias is extensively summarized elsewhere4.  
 
3.4. Thermal stimuli  
Six studies have performed regular quantitative sensory testing of thermal detection and pain 
thresholds in lesional and/or non-lesional skin of chronic itch patients (Table 4). For warmth and 
cold detection thresholds, 4 out of 6 studies found no significant differences,6,84,96,101 while 
Yudina et al. (2011) reported significantly increasd detection thresholds of approximately 1°C 
for both warmth and cold detection in AD130 and Tey et al. (2016) reported increased warmth 
detection thresholds of 2.7°C in PLCA.113 Similarly, 3 out of 4 studies investigating cold pain 
thresholds found no significant changes,6,84,101 while Yudina et al. (2011) observed decreased 
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cold pain threshold (i.e. reduced sensitivity for cld).130 All studies uniformly report that contact 
heat pain thresholds are unchanged when comparing lesional and/or non-lesional skin of patients 
with chronic itch to healthy controls, while a single study assessing laser-evoked heat pain in 
prurigo nodularis found decreased pain threshold to this type of stimulation in both lesional and 
non-lesional skin.28 Two studies have specifically assessed warmth- and heat-evoked itch also in 
AD. Both Ikoma et al. (2004) and Schneider et al. (2018) report significant warmth- and heat-
evoked itch in lesional AD skin, even though such stimuli are exclusively perceived as 
innocuously warm or as burning pain in healthy subjects. Warmth- and heat-evoked itch 
phenomenologically correspond to warmth alloknesis and heat algoknesis, respectively.4 In non-
lesional AD skin, no significant differences were found in heat-evoked itch.44 Patients with 
chronic itch subjected to suprathreshold cold pain stimulation by the use of the cold pressor task 
exhibited either a decreased tolerance,62 or no difference with the controls.61  
 
3.5. Electrical stimuli 
Eleven studies applied electrical stimulation for sensory testing purposes in chronic itch patients 
(Table 5). Widely different stimulation methods, e.g., different electrodes, as well as stimulation 
paradigms, e.g., to measure itch sensitivity, endogen us itch modulation, or current perception 
thresholds, have been used. . The results of four studies assessing current perception thresholds 
are unaligned and show both reduced,56 unchanged,72,79 and increased53 perception thresholds in 
the patients. Only two of these studies specifically investigated lesional skin areas, which found  
reduced56 or unchanged 72 current perception thresholds. Electrical tolerance thresholds were 
mostly not significantly different 60–62; only one small study indicated enhanced sensitivity n the 
patients 60. Using an electrical stimulation paradigm designed to evoke itch, Ikoma et al. (2004) 
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found increased itch sensitivity in lesional skin of AD patients but no difference in itch 
sensitivity in PSO, nor differences in pain sensitivity in these patient groups. In non-lesional skin 
of AD patients, with the exception of one study showing increased sensitivity in the patients,79 
no changes in electrically evoked itch sensitivity were observed in two studies using similar 
methodology,44,45, and another study.60 Patients with PSO responded less sensitive to non-
lesional electrical itch induction,61 and patients with chronic post-burn itch (CPBP) did not differ 
from their controls.62 Pain induced by the electrical inductions was generally not different 
between the patients (AD, PSO, and CPBP) and controls, but Yudina et al. (2011) found 
decreased pain thresholds in patients with AD.130 Of the two studies using electrical stimulation 
in a paradigm to assess conditioned itch modulation, reduced modulatory efficacy was observed 
in PSO patients,61 but not in patients with chronic post-burn itch (CPBP).62 
 
4. Discussion 
The main findings of the present systematic review and meta-analysis support the notion that 
patients with chronic itch display alterations in somatosensory sensitivity to a wide range of 
stimulations in lesional skin, while findings from non-lesional skin are less clear. Studies have 
predominantly been conducted in patients with AD; the only itch diagnosis for which aggregated 
meta-analytic evidence was present. Next, studies are characterized by substantial heterogeneity 
in terms of recruitment criteria, methodology, outcome reporting, and study design.  
 
Specifically, in lesional skin areas, increased itch responses are observed to chemical pruritogens 
(predominantly histamine, but also cowhage), algogens ( .g., bradykinin), and to mechanical as 
well as thermal stimuli. The observed sensory altertions predominantly take the form of 
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increased itch responsivity as opposed to altered detection and pain thresholds. However, meta-
analytic evidence is only conclusive for increased lesional histaminergic itch sensitivity in AD. 
This is mainly due to a low number of studies for other stimulation modalities and populations 
other than AD. In non-lesional skin of chronic itch patients, several studies indicate that 
histaminergic sensitivity is unaltered or decreased. Certain non-histaminergic provocations, 
chiefly cowhage, are found to evoke increased itch in non-lesional skin in some,6,32 but not all 
studies.71,75 Likewise, several studies suggest generalized punctate hyperknesis in non-lesional 
skin,60 but this observation is not uniform across studies.44 Hence, altered somatosensory 
processing appears to occur in lesional skin of patients with AD suffering from chronic itch, 
while it remains unclear if and in what way sensory sensitivity is robustly changed in non-
lesional skin, in patient groups other than AD, andwhether such potential changes correspond to 
the generalized increased pain sensitivity often repo t d in chronic pain patients.8,128  
 
4.1 Heterogeneity of studies 
Surprisingly, little heterogeneity is present in terms the studied conditions. AD is by far the most 
thoroughly investigated diagnosis with 32 of 46 studies exclusively including AD patients. Other 
major itchy dermatoses such as PSO and PN have only been investigated with sensory testing in 
2 studies each, and patients with urticaria and sensitive skin have only been included in a single 
study. It is rarely clear whether a convenience, consecutive, or systematic sample of patients is 
used (Fig. 2, see ‘Recruitment procedure’). Studies also differ in terms of diagnostic criteria and 
the duration of itch at the time of patient enrolment as well as how chronic itch is defined is often 
not reported (Fig. 2, see ‘Inclusion/exclusion criteria’). The latter is unsurprising given that a 
consensus definition of chronic itch was only proposed by the International Forum for the Study 
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of itch in 2007.108 Studies also differ widely in terms of medication allowance, which ranges 
from complete termination, or partial termination (e.g. for antihistamine or topical corticoids) to 
no medication changes at all (see Table 1). Sensory testing in chronic itch patients is often 
heterogeneous in terms of methodology and rarely standardized; there is no gold standard for 
most stimuli used to test itch sensitization (Fig. 2, see ‘Standardization of somatosensory 
assessment’). In addition, these methods have oftenbe  derived from the psychophysical pain 
research area.4 As such, the methodology is frequently applied in way which is different from its 
original intention. For example, multiple studies have assessed heat pain thresholds in lesional 
skin of chronic itch patients.6,28,101,130 These all fail to find significant changes relating to the pain 
threshold. However, studies where heat pain threshold  r suprathreshold stimulations are 
conducted and patients are specifically asked to rate the associated itch, uniformly show heat 
hyperknesis in patients with chronic itch when compared to healthy controls.44,80,101 
Nevertheless, in order to draw conclusions in terms of itch sensitization, most important is that 
stimuli were applied in a similar manner in both the patients and controls (e.g., at the same 
anatomical location), which seems the case for most studies (also scored under ‘Method of 
somatosensory assessment’, Fig. 2). Lastly, heterogeneity across studies is inherent to certain 
chemical pruritic models. For instance, the use of cowhage is associated with difficulties in 
controlling administration and potential batch-to-batch variation. Cowhage, nonetheless, remains 
the ‘gold standard’ for non-histaminergic itch.5,50  
 
4.2 Confounding factors 
A previously articulated problem with sensory testing and administration of chemical pruritogens 
in skin conditions relates to skin barrier alterations, which, unrelated to changes in neuronal 
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sensitivity, might alter sensory responsivity.4,6 Decreased skin barrier integrity is well known 
both in lesional and non-lesional skin of patients with AD.47,111,123 Responses to chemical 
provocations, particularly when delivered by iontoph resis, might be exaggerated in such areas. 
Similarly, skin micro-environment changes can interfere with normal local tissue clearance and 
might thus alter itch sensitivity to chemical provocations. In contrast, the perception of 
mechanical or heat stimulations might be reduced in lichenified (i.e. thickened) skin. These 
factors are rarely considered and may affect both lesional and non-lesional testing results. 
Moreover, most studies applied the stimuli on a standard anatomical location that is most 
frequently affected by the itch condition, e.g., the antecubital fossa in AD. Included studies 
labeled the findings at these locations as ‘lesional’, without taking into account any individual 
variations in the exact location of the lesion (e.g., lesionally versus peri-lesionally applied 
stimuli), the extent of the lesions, and the clinical morphology were not taken into account. 
Consequently, for this review, data were categorized as ‘lesional’ and ‘non-lesional’. In addition, 
also individual psychosocial factors, such as anxiety, attention, expectations, and mood, might be 
associated with itch sensitivity and bias sensory testing results.11,58,59,97,117 
 
4.3 Histaminergic or non-histaminergic itch sensitization? 
Itch sensitivity to chemical provocations is by farthe most thoroughly investigated aspect of the 
somatosensory status of chronic itch patients (Table 1).41 Chemical itch provocations are often 
classified based on their antihistamine-recalcitrance as either histaminergic (e.g. histamine, 
compound 48/80 or substance P) or non-histaminergic (e.g. cowhage or SLIGKV), but numerous 
compounds fall somewhere in between (e.g. bradykinin a d serotonin).5,43  
 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
   23 / 29
Levels of itch evoked by histamine (the most frequently applied pruritogen, Table 1) are 
significantly higher in lesional skin of the patients, particularly AD, than in healthy subjects (Fig. 
4), but no significant differences are evident for non-lesional skin (Fig. 3). The restriction to 
lesional areas indicates peripheral sensitization which could involve increased histamine-
responsiveness of mechano-insensitive C-fibers in lesional, inflamed skin.4,6,46 Sensitization of 
such fibers would also increase pruritic responses to certain peripheral inflammatory mediators, 
for instance bradykinin, which has indeed been observed.43 Important drivers of skin 
inflammation in AD are type-2 cytokines such as IL-4 and IL-13.123 While these cytokines have 
not yet been applied as human itch provocations, recent preclinical results show that they act 
directly on pruriceptive afferents to increase their r sponsiveness, for instance to histamine.78 
This provides a putative mechanism for the lesional histaminergic sensitization observed in 
chronic itch patients.78  
 
Studies that have attempted to assess itch sensitization in response to purely non-histaminergic 
itch provocations applied cowhage or SLIGKV (Fig. 5).109 There is some overlap in the receptors 
they target, e.g., PAR2/4 and/or certain Mas-related G-protein-coupled receptors .86,89 In non-
lesional AD skin, three of four studies found SMDs of 0.6 to 0.84 in favor of increased itch 
responses in the patients.6,32,109 However, the fourth study found an insignificant decrease in 
cowhage-evoked itch in AD patients,75 potentially as a consequence of unusually high itc
ratings in the control group causing a ceiling effect. In lesional skin of AD patients, two studies 
found robustly increased itch sensitivity,6,109, whereas a study in alopecia found no significant 
alterations in itch sensitivity (Table 2).96  
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Of the 14 additional pruritogenic or algogenic substances, including acetylcholine, bradykinin, 
citrate buffer (low pH-solution), compound 48/80, IL-31, VIP, substance P, serotonin, mustard 
oil, and prostaglandin E2, most have been applied only in a couple of studies and often only in 
non-lesional skin (Table 2). Of the above substances with pruritic properties, most are thought to 
evoke itch at least partially through histaminergic mechanisms but are less effective and less 
‘purely’ itch-inducing as compared to histamine.5,41,43 Overall, these studies have yielded 
negative results or have findings which have not been reproduced. Of note, several studies have 
shown increased itch responses within lesional skinto common algogens, e.g., bradykinin or 
citrate buffer, conceivably constituting a modality-switch type of sensitization.43,44 Analogues 
observations have been made when applying normally painful heat stimuli (see 4.5). The 
mechanism(s) behind this kind of perceptual abnormality is not yet established, but conceivably 
involves both central and peripheral processes. A recent review further discussing this sensory 
phenomenon is available.4 
 
4.4 Reduced neurogenic inflammatory reactivity 
A significantly decreased axon-reflex-flare size on non-lesional skin in response to histamine is 
clearly evident in AD (i.e. in 11 out of 12 studies), which is corroborated by a single study that 
included patients with urticaria (Fig. 6). Oppositely, no significant differences are present in PSO 
or SS. Other substances, such as acetylcholine, substance P, IL-2, VIP and compound 48/80, 
evoked similarly or less neurogenic flare in non-lesional skin in the patients (almost exclusively 
AD) when compared to the controls (Table 2). Provocati ns were mostly done in non-lesional 
skin due to difficulties associated with standardization, measurement methodology, and potential 
ceiling effects of neurogenic flare assessment in lesional skin (due to pre-existing skin 
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inflammation).6,85 The mechanisms behind this reduced neurogenic inflammatory responsiveness 
to histamine are unknown but appear to corroborate the subset of studies which find reduced 
histaminergic itch sensitivity in non-lesional skin.37,43,46 This may be related to altered 
biophysical skin properties4 or medication interference (many antihistamines have long plasma 
half-lives displaying considerable inter-variability).129 Other potential mechanisms include 
adaptive neuronal responses such as receptor downregulation within the microvascular or 
neuronal component or neuroanatomical changes in epidermal skin innervation,6,37,46,83,120 but 
little evidence supports these hypotheses. Either way, the present meta-evidence suggests a 
robust decrease in axon-reflex-flare responsiveness in AD to histamine and various other 
chemical provocations but does not find significantly reduced accompanying itch. Since the 
axon-reflex-flare is a proxy measure of activity in primary afferent C-fibers this is a notable 
mismatch. This can principally be explained by: 1) reduced activity of the receptive primary 
pruriceptors, after which itch-signaling is amplified in the spinal processing,46 or 2) decreased 
secretory capacity of the C-fibers or decreased responsiveness of the micro-vascular component, 
which is potentially independent of neuronal responses. The robust difference in neurogenic 
inflammatory capacity between patients with AD and healthy controls might be clinically 
applicable. A recent experimental study suggested th  possibility of using skin responses to 
diagnose mild or unusual cases of AD.32 It should be noted that there is little evidence on 
neurogenic inflammatory reactions in response to prvocations specifically activating non-
histaminergic pruriceptors.32 This is likely in part because the predominant human odel of non-
histaminergic itch relies on cowhage spicules evoking no/or very limited cutaneous erythema in 
healthy subjects which can only be accurately measur  by specialized flowmetric devices. 
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4.5 Itch sensitization to mechanical, thermal, and electrical stimuli  
It was not possible to compile quantitative meta-anlytic data on the sensitivity of chronic itch 
patients to mechanical, thermal, and electrical stimuli, due to the limited studies available that 
were characterized by substantial heterogeneity (See semi-quantitative overviews; Tables 3-5).  
 
Despite of research showing lowered lesional intra-epidermal nerve-fiber density in chronic itch 
patients,48,83, abnormalities in mechanical thresholds have only been sparsely investigated (Table 
3). The presently conducted semi-quantitative comparisons build upon the theory outlined in our 
previous narrative review on mechanical itch dysesth sias.4 Phenomenologically alloknesis and 
hyperknesis are analogous to the pain associated phnomena allodynia and hyperalgesia, which 
are often observed in pain conditions. However, recently the assumption that these sets of 
sensory phenomena also have analogous underlying mechanisms has been challenged. Two 
studies have found mechanical detection thresholds (a perceptual correlate of Aβ-fiber function) 
to be increased (i.e. reduced sensitivity) intra-lesionally in AD,6,101 but other studies show these 
thresholds to be decreased or unchanged in lesional skin of PN.28,84 These findings and their 
potential implications in the pathoetiology of different itch conditions remains to be further 
explored. Particularly, one has to consider the possibility that scabbed or lichenified skin might 
alter the force transduction properties of very low intensity punctate stimulation.4 On the other 
hand, reduced Merkel cell density has been implicated in xerotic itch and in the development of 
mechanical alloknesis through a spinal disinhibition f itch transmission.16,25 Mechanical 
hyperknesis to punctate stimuli is documented to occur within lesional skin, but it is unclear 
whether it exists robustly outside of lesions.6,44,60,101 Several studies indicate non-lesional 
hyperknesis,6,60,101 while others find no significant differences.44 Notably, allo- and hyperknesis 
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to mechanical stimuli (and warmth) are commonly repo ted natural features of AD, even though 
the well-controlled evidence to support this is seemingly scarce.6,23,77,120 Alloknesis to brush 
strokes appears to be restricted to lesional and perilesional skin and likely require more or less 
ongoing pruriceptive input to a spinal sensitization circuitry.4,80 However, recent mechanistic 
evidence suggests that peripheral dysfunction of Aβ- ibers mediating touch might play a role by 
altering the spinal gating exerted by tactile signaling on pruriceptive transmission.25 Note that 
mixed terminology pertaining to allo- and hyperknesis has previously been applied. In this 
review we apply the terms as defined in Andersen et al. 2018.4  
 
Warmth alloknesis and heat lgoknesis4 appear to exist robustly in lesional AD skin,44,101 but not 
in non-lesional skin (Table 4).101 The detection of sensory aberrations in response to thermal 
stimulation highlights a problem associated with lesional testing where itch intensity is the 
outcome. Either a lesion, which prior to the sensory test is completely itch-free is required, or it 
will inherently be unclear whether the evoked itch is in fact thermally induced versus itch evoked 
by simply meddling with the lesional skin, e.g. when attaching the thermal probe. While thermal 
probing appears to cause itch in lesional skin of itch patients, most studies have found that 
thermal detection and pain thresholds per se are not significantly altered (Table 4).  
 
No definite conclusions can be drawn from the data on electrical stimulation (Table 5). 
Regardless of whether the applied electrical stimulation paradigm is intended to evoke itch or 
simply measures the current perception threshold, fin ings display limited concordance between 
studies. This may be due to data incongruousness, the low number of studies, and 
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methodological heterogeneity, e.g., variation in geom try and application of the applied 
electrodes, the electrical stimulation paradigms applied as well as the body location tested. 
 
4.6 Conclusion 
This systematic review and meta-analysis support the notion that somatosensory sensitivity to a 
wide range of stimulations is present in the lesional skin (probable primary sensitization) of 
patients with chronic itch (primarily AD). This is in part analogous to the body of evidence 
suggesting sensitization in chronic pain.8,128 Unlike for pain conditions, limited evidence favor 
robust non-lesional sensitization in chronic itch (at least with the current testing paradigms and 
patient populations). This indicates that sensitizat on of itch measured by psychophysical 
assessments might manifest in a less centralized manner, at least in patients with AD, as 
compared to pain. Moreover, sensory phenotypes with distinct sensitization and loss-of-function 
profiles have been uncovered in chronic pain disorders, but have not yet been thoroughly 
assessed in the context of itch.6 
 
Evidence in favor of lesional sensitization to histamine provocations in AD is evident. In lesional 
skin, increased itch responses to other pruritogens, to ome algogens, and to mechanical as well 
as thermal stimuli are semi-quantitatively apparent. Moreover, meta-analytic evidence 
conclusively shows reduced neurogenic inflammatory responses in patients with AD with data 
compiled from 12 studies. Based on 18 studies, chronic itch patients in general, and patients with 
AD in particular, do not have significantly altered sensitivity to histamine provocations in non-
lesional skin. Results analogous to those for histamine were found for cowhage/SLIGKV 
although much fewer studies have been conducted using these non-histaminergic itch stimuli (6 
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studies in non-lesional skin and only 2 in lesional skin). The semi-quantitative analysis did not 
provide conclusive results as to the potential sensory aberration occurring in non-lesional skin, 
but a majority of studies reported punctate hyperknsis. The included studies are cross-sectional, 
are characterized by heterogeneity in several important domains, rarely investigate correlations 
between psychophysical findings and clinical characteristics, and have predominantly been 
conducted in patients with AD.  
 
Measuring itch sensitization could have potential clinical utility, for instance for the purpose of 
enhancing individualized prognosis and treatment. However, a consolidation of the taxonomy 
used to describe itch sensitization signs as well as more standardized and uniform 
psychophysical testing approaches are needed. Moreover, longitudinal studies comparing itch 
sensitization outcomes with clinical characteristics as well as disease burden in larger and more 
diverse patient samples are required to adequately elucidate somatosensory changes and their 
implications in patients suffering from chronic itch.  
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Table 1 Characteristics of included studies, including characteristics of the patient and healthy control sample and the somatosensory 
tests / provocations 
Study data Patient and healthy controls characteristics Somatosensory tests / provocations 
First 
author 
Publicati
on year 
Patient 
populatio
n 
Sampl
e size 
patient
s 
Sampl
e size 
HC 
Medicat
ion 
allowed 
Mean age 
patients (y) 
Mean 
age HC 
(y) 
Sex 
Lesion
al skin 
tested 
Mechanic
al 
Electric
al 
Chemic
al 
Therm
al 
Amatya et 
al.3 
2010 PSO 15 15 0 41.2 39.5 
m + 
f 
yes + 
no  
no no yes no 
Andersen 
et al.6 
2017 AD 25 25 1 25.2 26.3 
m + 
f 
yes + 
no 
yes no yes yes 
Bin Saif et 
al.96 
2013 CCCA 16 15 2 44 39 f 
yes + 
no 
no no yes yes 
Falcone et 
al. 24 
2017 SS 9 9 0 21 21 
m + 
f 
Yes no no yes no 
Gronroos 
et al.28 
1997 PN 5 5 1 40-70 a 29-54 a 
m + 
f 
yes + 
no 
yes no yes yes 
Hawro et 
al.33 
2014 AD 10 10 1 30.7  31.2  
m + 
f 
no no no yes no 
Hawro et 
al. 32 
2016 AD 22 18 0 30 b 29 b 
m + 
f 
no no no yes no 
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Heyer et 
al. 36 
1989 AD 27 20 1 23.0 28.8 
m + 
f 
no  no no yes no 
Heyer et 
al.35 
1991 AD 20 20 1 26.4 31.8 
m + 
f 
no no no yes no 
Heyer et 
al.38 
1995 AD 19 20 1 30 26 
m + 
f 
no yes no yes yes 
Heyer et 
al.39 
1997 AD 15 15 1 24-38 a 17-36 a 
m + 
f 
no no no yes no 
Heyer et 
al.37 
1998 Mixed 64 16 0 
26 
(eczema-
free AD);  
27 (acute 
AD); 33 
(PSO); 26 
(URT) 
28 
m + 
f 
no  no no yes no 
Hosogi et 
al.43 
2006 AD 14 15 0 24.5 28.2 
m + 
f 
yes + 
no 
yes no yes no 
Ikoma et 
al.46 
2003 Mixed 
18 
(AD); 
6 
(PSO) 
15 1 
24.5 (AD); 
27.5 (PSO) 
28.7 
m + 
f 
yes + 
no 
no no yes no 
Ikoma et 2004 Mixed 34 20 0 25.6 (AD) 29.5 m + yes + yes yes yes yes 
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al.44 44.2 (PSO) f no 
Ikoma et 
al.45 
2005 AD 10 20 0 24.7 33.1 
m + 
f 
no no yes yes no 
 Ishiuji et 
al.48 
2008 AD 16 10 2 34.3 34.3 
m + 
f 
yes + 
no 
yes no yes yes 
Ishiuji et 
al.49 
2009 AD 8 7 2 33.1 34.6 
m + 
f 
yes no no yes no 
Kobayashi 
et al.53 
2003 AD 25 30 2 23 24 
m + 
f 
n.r. yes yes yes no 
Koppert et 
al.54 
1996 AD 16 16 2 
Entire study 
population: 29.1 
m + 
f 
no no no yes no 
Krzanows
ka et al.56 
2015 Mixed 38 49 2 
37.8 (AD); 
44.6 (PSO) 
26.3 
m + 
f 
yes + 
no 
no yes no no 
Mochizuki 
et al.70 
2015 Mixed 10 10 n.r.  37.2 31.4 
m + 
f 
no no no yes no 
Mori et 
al.72 
2010 AD 
32 
(extrins
ic); 17 
(intrins
ic) 
24 2 
30.0 
(extrinsic); 
33.0 
(intrinsic) 
28.9 
m + 
f 
no no yes no no 
Nattkempe
r et al.75 
2015 AD 10 10 0 28 27 
m + 
f 
no no no yes no 
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Neisius et 
al.76 
2002 AD 8 8 1 26 25 
m + 
f 
no no no yes no 
Ozawa et 
al.79 
2009 AD 24 24 1 22.0 23.5 
m + 
f 
no  no yes no no 
Papoiu et 
al.81 
2011 AD 15 15 1 32.6 30.9 
m + 
f 
no no no yes no 
Pereira et 
al.84 
2017 PN 12 8 2 50 49 
m + 
f 
yes yes no no yes 
Rasul et 
al.85 
2013 AD 25 25 1 31.1 30.4 
m + 
f 
no no no yes no 
Rukwied 
& Heyer 92 
1998 AD 24 14 0 
26 (acute);  
28 (non-
acute) 
25 
m + 
f 
no no no yes no 
Rukwied 
et al.91 
1999 AD 14 14 0 31 28 
m + 
f 
no no no yes no 
Rukwied 
et al.94 
2000 AD 9 9 1 28 27 
m + 
f 
no no no yes no 
Schneider 
et al.100  
2008 AD 8 6 1 31.4 29 
m + 
f 
no no no yes no 
Schneider 
et al.101 
2018 Mixed 33 30 0 51 48.6 
m + 
f 
yes  yes no no yes 
Steinhoff 2003 AD 38 33 1 25.4 26.5 m + yes + no no yes no 
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et al.109  f no 
Tey et 
al.113 
2016 PLCA 20 20 2 61.0 59.5  
m + 
f 
yes no no no yes 
Tran et 
al.115 
2010 AD 21 24 0 31.8 28.9 
m + 
f 
n.r. yes yes yes no 
van 
Laarhoven 
et al.60  
2007 AD 15 19 2 33.2 43.3 f 
primari
ly yes 
yes yes no no 
van 
Laarhoven 
et al.61 
2010 PSO 25 31 2 47 52 f no no yes yes yes 
van 
Laarhoven 
et al.62 
2016 
CPBP 
 
 
15 15 2 41.6 41 
m + 
f 
no yes yes yes yes 
Vogelsang 
et al.118 
1995 AD 15 15 0 17-36 a 24-38 a 
m + 
f 
no no no yes no 
Wahlgren 
& Ekblom 
119 
1996 AD 20 20 0 25 b 28 b 
m + 
f 
n.r. yes no yes no 
Wahlgren 
et al.120  
1990 AD 32 32 1 24 b 22 b 
m + 
f 
no (yes 
for 
wool) 
yes no yes no 
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Wahlgren 
et al.122 
1995 AD 8 8 1 24.0 19.5 
m + 
f 
no no no yes no 
Weisshaar 
et al.126  
1998 AD 12 12 1 27.5 29 
m + 
f 
no yes no yes no 
Yudina et 
al.130 
2011 AD 
38 
(electr)
; 22 
(therm) 
26 
(electr)
; 15 
(therm) 
2 23.5 25 
m + 
f 
n.r. no yes no yes 
Legend: arange; bmedian 
 
Abbreviations: AD: Atopic Dermatitis; CPBP: chronic post-burn itch; CCCA: Central centrifugal cicatricial Alopecia; HC: healthy 
controls; PLCA: Primary localized cutaneous amyloidosis; PN: Purigo Nodularis; PSO: Psoriasis; SS: sensitive skin; URT: urticaria; 
Mixed: various skin diseases; electr: electrical; therm: thermal; f: female; m: male; n.r.: not reported; y: years 
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Table 2 Semi-quantitative analyses of somatosensory outcomes for chemical provocations which 
were applied in less than 5 studies (no quantitative meta-analysis was conducted for these 
outcomes). The table displays whether the patients were significantly (p<0.05) more sensitive, 
significantly (p<0.05) less sensitive or not significantly different from the healthy controls. See 
separate rows for results from lesional and non-lesional skin.  
  Responses to chemical provocations 
Outcome Skin 
area 
Patients 
significantly less 
sensitive 
No significant difference Patients significantly 
more sensitive 
Itch 
AUC/M 
Lesional Bradykinin in 
AD* 43 
5-HT in AD43; Citrate buffer in 
PSO44; Substance P in AD43 and 
in PSO3 
Citrate buffer in AD44; 
Cowhage in AD6; 
SLIGKV in AD109 
Non-
lesional 
5-HT in AD*43; 
VIP91 
5-HT in AD85; Acetylcholine in 
AD39,91,118 Bradykinin in AD43; 
Compound 48/80 in AD94,120; IL-
2 in AD122; IL-31 in AD33; 
Prostaglandin E2 in AD76, 
SLIGKV in AD109; Substance P 
in AD35,43 and PSO3; VIP in 
AD92 
Citrate buffer in AD44; 
Cowhage in AD 6,32 
Peak itch Lesional  Substance P in PSO3; Cowhage 
in CCCA96 
Cowhage in AD6  
Non-
lesional 
 5-HT in AD85; Codeine in 
AD109; Compound 48/80 in 
AD121; Cowhage in AD6,32 and 
CCCA96; IL-31 in AD33; 
Substance P in PSO3 
 
Itch peak 
latency 
Lesional  Substance P in PSO3 Histamine in PSO3 
Non-
lesional 
Substance P35 5-HT in AD85; Histamine in 
AD85 and PSO3; IL-31 in AD33; 
Substance P in PSO3 
Acetylcholine in 
AD39,118 
Pain 
AUC/M 
Lesional  5-HT in AD43; Citrate buffer in 
AD and PSO44; Cowhage in 
AD6; Histamine in AD43; 
Substance P in AD43 
Bradykinin in AD43 
Non-  5-HT in AD43; Acetylcholine in  
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lesional AD91; Bradykinin in AD43; 
Cowhage in AD6; Histamine in 
AD43; Substance P in AD43; VIP 
in AD91 
Flare area Lesional Histamine in 
AD43 
5-HT in AD43; Bradykinin in 
AD43; Histamine in AD46,48; 
Substance P in AD43 
 
Non-
lesional 
5-HT in AD85; 
Acetylcholine in 
AD91;  
Compound 48/80 
in AD94,120; IL-2 
in AD122; 
Substance P in 
AD35,43 VIP in 
AD91,93 
  
5-HT in AD43; Acetylcholine in 
AD39,118; Bradykinin in AD43; 
IL-31 in AD33; mustard oil in 
AD35; Prostaglandin E2 in AD76; 
Substance P in PSO3 
 
Flare 
intensity 
Lesional    
Non-
lesional 
Substance P in 
AD35; Histamine 
in AD 6 
Cowhage in AD32; Histamine in 
AD32,36; IL-31 in AD33; Mustard 
oil in AD35; Prostaglandin E2 in 
AD76 
Acetylcholine in 
AD39,118; VIP in AD93  
 
Abbreviations: 5-HT: Serotonin; AD: Atopic Dermatitis; AUC: area under the curve; CPBP: 
chronic post-burn itch; IL: interleukin; M: mean; PLCA: Primary localized cutaneous 
amyloidosis; PSO: Psoriasis; mixed CP: various skindiseases; VIP: vasoactive intestinal 
polypeptide. Asterisk (*); not statistically compared in original paper, but assumed based on 
other reported significant differences. 
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Table 3 Semi-quantitative analyses of somatosensory outcomes for mechanical stimuli which 
were applied in less than 5 studies (no quantitative meta-analysis was conducted for these 
outcomes). The table displays whether the patients were significantly (p<0.05) more sensitive, 
significantly (p<0.05) less sensitive or not significantly different from the healthy controls. See 
separate rows for results from lesional and non-lesional skin.  
  Responses to mechanical stimuli 
Outcome Skin area Patients 
significantly 
less sensitive 
No significant 
difference 
Patients 
significantly more 
sensitive 
Mechanical detection 
threshold 
Lesional AD6; Mixed 
CP101 
 
PN84 PN28 
Non-lesional  AD6  
Mechanical 
pain/pressure pain 
threshold 
Lesional  MPT in AD6 
and in PN84; 
PPT in PN84; 
Von Frey in 
AD60 
MPT in mixed CP101 
Non-lesional  MPT in AD6 Von Frey in AD60 
Itch AUC/M/Peak 
(alloknesis/hyperknesis 
prior to itch 
provocation) 
Lesional  Pin prick in 
PSO44 
Pin prick in AD44 and 
mixed101 Von Frey in 
AD6,60; Wool in 
AD120 
Non-lesional  Von Frey in 
CPBP57  
Pin prick in AD44; 
Von Frey in AD6,60; 
Wool in AD120  
Mechanically evoked Lesional  Pin prick in Pin prick in AD6 and 
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pain/mechanical pain 
sensitivity 
AD and PSO44 
and in PN84; 
Von Frey in 
AD60 
in mixed CP101 
Non-lesional  Pin prick in 
AD44; Von 
Frey in AD60 
Pin prick in AD6 
Development of 
mechanical 
alloknesis/hyperknesis 
after itch provocation 
Lesional  After 
histamine in 
AD6 
After cowhage in 
AD6 
Non-lesional 
 
 
After 
histamine in 
AD38,126 
After 
electrical itch 
in AD45; After 
histamine in 
AD6 
After cowhage in 
AD6 
Two-point 
discrimination 
Lesional    
Non-lesional  Discrimination 
of touch in 
AD119 
Discrimination of itch 
in AD119  
 
Abbreviations: AD: Atopic Dermatitis; AUC: area under the curve; CPBP: chronic post-burn 
itch; M: mean; MPT: mechanical pain threshold; PLCA: Primary localized cutaneous 
amyloidosis; PN: Purigo Nodularis; PSO: Psoriasis; mixed CP: various skin diseases; PPT: 
pressure pain threshold  
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Table 4 Semi-quantitative analyses of somatosensory outcomes for thermal stimuli which were 
applied in less than 5 studies (no quantitative meta-analysis was conducted for these outcomes). 
The table displays whether the patients were significantly (p<0.05) more sensitive, significantly 
(p<0.05) less sensitive or not significantly different from the healthy controls. See separate rows 
for results from lesional and non-lesional skin. 
  Responses to thermal stimuli 
Outcome Skin area Patients 
significantly 
less sensitive 
No significant difference Patients significantly 
more sensitive 
Warmth 
detection 
threshold 
Lesional PLCA113  AD6; CCCA96; PN84; 
Mixed101 
 
Non-lesional AD130 AD6; CCCA96  
Heat pain 
threshold 
Lesional  AD6; CCCA96; PN84; 
PLCA113; Mixed101 
 
Non-lesional  AD6,130; CCCA96  
Laser 
pain 
threshold 
Lesional   PN28 
Non-lesional   PN28 
Cold 
detection 
threshold 
Lesional  AD6; PN84; Mixed101  
Non-lesional AD130 AD6  
Cold pain 
threshold 
Lesional  AD6; PN84; Mixed101  
Non-lesional AD130 AD6  
Cold pain 
tolerance 
Lesional 
 
   
Non-lesional  PSO61 CPBP62  
     
    
Itch 
induced 
by 
thermal 
stimuli 
 
 
Lesional   Heat in AD44; warmth, 
cold, heat pain, cold 
pain in mixed CP101 
Non-lesional  Heat in AD44  
Pain Lesional  Heat in AD44  
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induced 
by 
thermal 
stimuli 
Non-lesional  Heat in AD44  
Abbreviations: AD: Atopic Dermatitis; AUC: area under the curve; CPBP: chronic post-burn 
itch; M: mean; PLCA: Primary localized cutaneous amyloidosis; PN: Purigo Nodularis; PSO: 
Psoriasis; mixed: various skin diseases  
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Table 5 Semi-quantitative analyses of somatosensory outcomes for electrical stimulation which 
were applied in less than 5 studies (no quantitative meta-analysis was conducted for these 
outcomes). The table displays whether the patients were significantly (p<0.05) more sensitive, 
significantly (p<0.05) less sensitive or not significantly different from the healthy controls. See 
separate rows for results from lesional and non-lesional skin. 
  Responses to electrical stimulation 
Outcome Skin 
area 
Patients significantly 
less sensitive 
No significant difference Patients significantly 
more sensitive 
Current 
perception 
threshold 
Lesional AD56; PSO56 AD72  
Non-
lesional 
AD56; PSO56 AD72,79 AD53 
Conditioned 
itch 
modulation 
Lesional    
Non-
lesional 
 CPBP57 PSO61 
Electrical 
tolerance 
threshold 
Lesional  AD60  
Non-
lesional 
 PSO61; CPBP62 AD60 
Electrical 
pain 
threshold 
Lesional    
Non-
lesional 
  AD130 
Electrically 
induced itch 
Lesional  AD60; PSO44  AD44 
Non-
lesional 
PSO61 AD44,45,60; CPBP62 AD79 
 
Electrically 
induced 
pain 
Lesional AD44 AD60; PSO44  
Non-
lesional 
 AD44,45,60; PSO44,61; 
CPBP62 
 
Abbreviations: AD: Atopic Dermatitis; CPBP: chronic post-burn itch; PSO: Psoriasis 
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Figure legends 
Fig. 1. Flow diagram of the selection process of studies obtained by the search of the databases 
PubMed, Embase, and the Cochrane Library, including reasons for exclusion.  
Fig. 2. 
Risk of bias summary: review authors' judgments about each risk of bias item presented as perce
ntages across all studies included.  
Fig. 3. Forest plot of the random effects meta-analysis for the outcome mean/area under the 
curve (AUC) itch during histamine provocations on non-lesional skin of patients and healthy 
controls. Abbreviations: AD: Atopic Dermatitis; CCCA: Central centrifugal cicatricial Alopecia; 
CI = confidence interval; PSO: Psoriasis; Std. = standardized. 
Fig. 4. Forest plot of the random effects meta-analysis for the outcome mean/area under the 
curve (AUC) itch during histamine provocations on lesional skin of patients and healthy controls. 
Abbreviations: AD: Atopic Dermatitis; CCCA: Central centrifugal cicatricial Alopecia; CI = 
confidence interval; PSO: Psoriasis; Std. = standardized 
Fig. 5. Forest plot of the random effects meta-analysis for the outcome mean/area under the 
curve (AUC) itch during non-histaminergic itch provocations (cowhage and SLIGKV)  on non-
lesional skin of patients and healthy controls. Abbreviations: AD: Atopic Dermatitis; CCCA: 
Central centrifugal cicatricial alopecia; CI = confidence interval; PSO: Psoriasis; Std. = 
standardized 
Fig. 6. Forest plot of the random effects meta-analysis for the outcome area of neurogenic 
inflammation (flare area) following histamine provocations in non-lesional skin of patients and 
healthy controls. Abbreviations: AD: Atopic Dermatitis; CCCA: Central centrifugal cicatricial 
Alopecia; CI = confidence interval; PSO: Psoriasis; Std. = standardized 
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